1. Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma 
Tao Jiang, Andrew X. Zhu, Dushyant V. Sahani 
Journal of Hepatology 
Volume 58, Issue 1, Pages (January 2013)
DOI: /j.jhep
Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

2. Fig. 1
Serial contrast enhanced CT images. The images were obtained (A) before, (B) at 2months and (C) after 4months of sorafenib treatment in a 56-year-old woman with multifocal HCC. A gradual decrease in tumor viability (increased necrosis) of the dominant mass can be observed. At 4months, >50% of the tumor is non-viable while the tumor burden measurement by RECIST and WHO has increased.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

3. Fig. 2
Transverse CT grey scale images after enhancement and corresponding functional perfusion CT maps for the estimated blood flow (BF) at pre- and 2 weeks post-treatment with bevacizumab antiangiogenic therapy in a 59-year-old man with HCC. There was an obvious decrease in the enhancement and perfusion of HCC.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

4. Fig. 3
Functional transfer constant (Ktrans) maps from MR perfusion for early response monitoring in sunitinib antiangiogenic therapy. Ktrans is one of the hemodynamic parameters in dynamic MRI for vessel permeability measurements. After 2 weeks of treatment with sunitinib, HCC showed a 96% drop of Ktrans in the 47-year-old man with positive tumor response, which presented a conspicuity of permeability change in HCC.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

5. Fig. 4
Transverse arterial phase CE-MRI image and a corresponding ADC map from DW-MRI performed before and 4 weeks after TACE are shown. There is complete devascularization in the HCC (arrow) evident as reduced tumor enhancement on the follow-up CE-MRI (A and B). Similarly, there is an obvious increase in the tumor ADC (arrow) from baseline, confirming the treatment effectiveness (C and D).
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

6. Journal of Hepatology 2013 58, 169-177DOI: (10. 1016/j. jhep. 2012. 08
Copyright © 2012 European Association for the Study of the Liver Terms and Conditions